T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mondelez International
MDLZ
|
+$841M |
| 2 |
Liberty Global Class C
LBTYK
|
+$752M |
| 3 |
Apple
AAPL
|
+$720M |
| 4 |
Tesla
TSLA
|
+$713M |
| 5 |
NXP Semiconductors
NXPI
|
+$648M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.2B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.03B |
| 3 |
Gilead Sciences
GILD
|
+$917M |
| 4 |
Pfizer
PFE
|
+$901M |
| 5 |
Nike
NKE
|
+$872M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.88% |
| 2 | Consumer Discretionary | 14.86% |
| 3 | Financials | 14.2% |
| 4 | Technology | 12.51% |
| 5 | Industrials | 9.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SUPV
1426
Grupo Supervielle
SUPV
$738M
| $3.65M | ﹤0.01% |
+285,200
| New | +$3.42M |
|
1427
ResMed
RMD
$32.9B
| $3.6M | ﹤0.01% |
56,897
+3,932
| +7% | +$232K |
|
|
PBNC
1428
DELISTED
PARAGON COMMERCIAL CORPORATION
PBNC
| $3.55M | ﹤0.01% |
+101,400
| New | +$3.53M |
|
1429
SPS Commerce
SPSC
$2.86B
| $3.48M | ﹤0.01% |
114,880
-1,826,684
| -94% | -$47.3M |
|
|
HZN
1430
DELISTED
Horizon Global Corporation
HZN
| $3.48M | ﹤0.01% |
306,496
-484,050
| -61% | -$5.77M |
|
1431
XPO
XPO
$24.7B
| $3.45M | ﹤0.01% |
380,030
+26,181
| +7% | +$260K |
|
|
WR
1432
DELISTED
Westar Energy Inc
WR
| $3.42M | ﹤0.01% |
60,966
-2,077
| -3% | -$110K |
|
1433
ICICI Bank
IBN
$106B
| $3.41M | ﹤0.01% |
522,409
+116,580
| +29% | +$750K |
|
1434
Cedar Fair
FUN
$1.71B
| $3.39M | ﹤0.01% |
58,626
-100
| -0.2% | -$5.85K |
|
1435
Groupon
GRPN
$894M
| $3.37M | ﹤0.01% |
51,894
+40,710
| +364% | +$3.01M |
|
1436
Mid-America Apartment Communities
MAA
$15.6B
| $3.35M | ﹤0.01% |
31,443
+640
| +2% | +$64.3K |
|
1437
Teladoc Health
TDOC
$1.26B
| $3.34M | ﹤0.01% |
208,750
-310,245
| -60% | -$3.62M |
|
|
EV
1438
DELISTED
Eaton Vance Corp.
EV
| $3.34M | ﹤0.01% |
94,545
+3,835
| +4% | +$135K |
|
|
PRFT
1439
DELISTED
Perficient Inc
PRFT
| $3.33M | ﹤0.01% |
163,900
-2,900
| -2% | -$60.1K |
|
1440
John B. Sanfilippo & Son
JBSS
$1.01B
| $3.32M | ﹤0.01% |
+77,890
| New | +$4.24M |
|
1441
National Fuel Gas
NFG
$7.75B
| $3.31M | ﹤0.01% |
58,222
-859
| -1% | -$46.4K |
|
1442
Synopsys
SNPS
$78.8B
| $3.3M | ﹤0.01% |
61,030
-2,262
| -4% | -$113K |
|
|
ICPT
1443
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $3.25M | ﹤0.01% |
22,785
-800
| -3% | -$117K |
|
|
MRUS
1444
DELISTED
Merus
MRUS
| $3.2M | ﹤0.01% |
+400,000
| New | +$3.5M |
|
|
EMWP
1445
DELISTED
Eros Media World PLC
EMWP
| $3.15M | ﹤0.01% |
9,670
-575
| -6% | -$151K |
|
|
EXAS
1446
DELISTED
Exact Sciences
EXAS
| $3.15M | ﹤0.01% |
256,700
+20,500
| +9% | +$154K |
|
|
CETV
1447
DELISTED
Central European Media Enterprises Ltd
CETV
| $3.08M | ﹤0.01% |
1,457,900
+129,000
| +10% | +$320K |
|
1448
Cheniere Energy
LNG
$55B
| $3.05M | ﹤0.01% |
81,166
+5,316
| +7% | +$187K |
|
1449
Annaly Capital Management
NLY
$17.6B
| $3.03M | ﹤0.01% |
68,456
+3,298
| +5% | +$140K |
|
1450
Team
TISI
$101M
| $3.03M | ﹤0.01% |
12,206
-3,550
| -23% | -$997K |
|
Similar funds
T. Rowe Price Associates's Q2 2016 Portfolio in Review
As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
- T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
- T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
- T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
- T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
- T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
- T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.
Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.